We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PER market cap is 67.62M. The company's latest EPS is AUD -0.0126 and P/E is -5.56.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 587k | 741k | 633k | 1.78M | 1.58M |
| Operating Income | -3M | -5.93M | -8.05M | -5.83M | -11.77M |
| Net Income | -2.94M | -5.91M | -8.06M | -5.81M | -11.38M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 3.7M | 5.35M | 7M | 22.44M | 12.84M |
| Total Liabilities | 889k | 821k | 1.27M | 1.3M | 2.87M |
| Total Equity | 2.81M | 4.53M | 5.73M | 21.14M | 9.98M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -2.93M | -3.95M | -5.83M | -7.81M | -8.15M |
| Investing | 2.4M | -10k | -8k | -4k | -29k |
| Financing | 1.53M | 5.11M | 7.8M | 21.02M | -86k |
| Market Cap | 67.62M |
| Price to Earnings Ratio | -5.56 |
| Price to Sales Ratio | 38.89 |
| Price to Cash Ratio | 5.74 |
| Price to Book Ratio | 6.33 |
| Dividend Yield | - |
| Shares Outstanding | 901.54M |
| Average Volume (1 week) | 3.66M |
| Average Volume (1 Month) | 1.2M |
| 52 Week Change | 29.31% |
| 52 Week High | 0.11 |
| 52 Week Low | 0.053 |
| Spread (Intraday) | 0 (3.9%) |
| Company Name | Percheron Therapeutics Ltd |
| Address |
14 wallace avenue melbourne, victoria 3142 |
| Website | https://www.antisense.com.au |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
